Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer | Cancer Today
Recent findings support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months.
Related Articles
Understanding Graft-VS-Host Disease (GVHD) Basics
Panelists discuss how graft-vs-host disease (GVHD) is a complex immune-mediated condition, highlighting the differences between acute and chronic GVHD, the associated risk factors, prognosis, and…
Metastatic Breast Cancer Support and Education | Dana-Farber Cancer Institute
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program at Dana-Farber Cancer Institute is to provide resources and information to…
ACS report: Cancer mortality continues to drop despite rising incidence in women – The Cancer Letter
Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report.…
FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials – The Cancer Letter
The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the…
Rathmell steps down at NCI as Trump team considers candidates to replace her Wafik El-Deiry, Harvey Risch have been interviewed – The Cancer Letter
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and…
What is royal jelly?
Royal jelly is a bee product, but it has many differences from honey. Here’s how royal jelly is made, the nutrients it contains and what…
Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLC
Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.
9 States Poised To End Coverage for Millions if Trump Cuts Medicaid Funding – KFF Health News
About 3.7 million people are at immediate risk of losing health coverage should the federal government cut funding for Medicaid expansions, as some allies of…
Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis
Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (Calquence) for Mantle Cell Lymphoma
Latest News The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16,
